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Improving Quality in the Care of Patients with Inflammatory Bowel 
Diseases
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Efforts to improve healthcare quality were firmly established before the Institute of Medicine (IOM) historic 2000 and 2001 reports, To Err is 
Human Building a Safer Health System and Crossing the Quality Chasm: A New Health System for the 21st Century Despite the long-standing 
healthcare quality improvement (QI) efforts that date back to the turn of the 20th century, the IOM reports significantly advanced the awareness 
of healthcare quality deficits and the resulting risk to patients from those gaps in care. Studies immediately following the IOM reports emphasized 
and verified the presence of detrimental care gaps and highlighted a myriad of contributing factors. Studies focused specifically on the inflam-
matory bowel diseases (IBD), Crohn's disease and ulcerative colitis , demonstrated suboptimal patient outcomes stemming from, in part, system 
and provider variation. In the years that have followed, research studies have shown the persistence of suboptimal outcomes in IBD despite an 
awareness of key drivers for poor care quality and concerted efforts in advancing QI initiatives. In 2017, IBD advocacy groups and provider net-
works have demonstrated progress in furthering both pediatric and adult IBD outcomes through the use of QI methods and tools including col-
laborative learning networks. A significant amount of work lies ahead, however, to build upon these advances and improve IBD outcomes further. 
This article reviews the history of quality initiatives in healthcare, identifies ongoing gaps in IBD care with a review of current IBD improvement 
efforts taking place, and identifies several targets for improving IBD care quality moving forward into the 21st century.
Key Words: inflammatory bowel disease, quality of care, quality improvement, outcomes, Crohn's disease, ulcerative colitis
INTRODUCTION
The inflammatory bowel diseases (IBD) are chronic 
illnesses classically comprised of Crohn’s Disease (CD), 
ulcerative colitis (UC), and indeterminate colitis (IC). These 
diseases are characterized by a waxing and waning inflamma-
tory course marked by signs and symptoms including diar-
rhea, weight loss, and debilitating abdominal pain with varying 
degrees of intestinal blood loss. The prevalence and incidence 
are increasing both in the United States (US) and worldwide.1–4 
In the US roughly 1.2 million individuals are affected by CD 
or UC.5 The estimated incidence rate in adults is 200 cases–240 
cases per 100,000 persons and is rising.6
Uncontrolled disease is expensive to treat and leads to a 
significant reduction in quality of life, lost productivity in work 
or school, and escalation in care either in the acute setting of 
the emergency room or through prolonged hospitalization. In 
the early 2000s, the financial burden of IBD on the health care 
system was estimated at nearly $6.3 billion annually.7 Though 
treatment expenses are a large portion of IBD costs, inappro-
priate therapies, lack of adherence, and suboptimal care has 
led to estimates of the total IBD cost burden to reach between 
$14.6 billion and $31.6 billion in 2014.8
In addition to the direct impact of the IBD process, 
these diseases also carry with them modifiable yet persistent 
risks of serious infections,9–11 invasive intestinal malignancies, 
12, 13 extraintestinal malignancies,14 and thrombotic events.15–17 
IBD increases the immediate and lifelong risk of mortality 
when compared to matched controls18 emphasizing the impor-
tance of care targeting risk reduction whenever and wherever 
possible.
Despite recent improvements in healthcare quality, IBD 
patients continue to struggle with suboptimal disease control, 
preventable disease complications, and negative consequences 
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of therapy including serious infections and cancer. Advancing 
the quality of IBD care is a critically important initiative. 
However, as the healthcare system evolves, so too should the 
approach to improvement efforts. To begin, understanding the 
current IBD quality landscape will better position care provid-
ers to maximize patient outcomes and remain engaged in pro-
ducing high value, reliable health care for the future.
The aims of this article are to (1) discuss the history of 
quality initiatives in healthcare, (2) review the ongoing gaps in 
quality of care with a focus on IBD, (3) highlight the challenges 
for quality improvement work in IBD, (4) review the current 
IBD improvement efforts taking place and their impact on care 
and outcomes, and (5) discuss a future roadmap for IBD qual-
ity improvement.
QUALITY INITIATIVES IN HEALTHCARE: EARLY 
BEGINNINGS
In 2000, the Institute of Medicine (IOM) issued a report, 
To Err is Human: Building a Safer Health System, quantifying 
an alarming rate of medical errors contributing to an unac-
ceptable number of hospital deaths. The focus of the report 
on patient safety shifted the spotlight away from individual 
providers contribution to medical errors and onto the “system 
of care.” In doing so, the IOM report challenged healthcare to 
design better processes of care that recognize and prevent med-
ical errors.19 Accomplishing such a task would bring healthcare 
more in line with the IOM vision for quality healthcare defined 
as “the degree to which health services for individuals and pop-
ulations increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge”.20
In 2001 the IOM published a second report titled, 
Crossing the Quality Chasm: A New Health System for the 21st 
Century. This report famously identified that “between the 
health care we have and the care we could have lies not just a 
gap, but a chasm”, providing a sobering reminder to care pro-
viders and health system leaders that health care needed signif-
icant improvement. In that 2001 report, the IOM defined 6 key 
dimensions needed for a health care system designed to improve 
the quality of care it delivered. These dimensions include care 
that is Safe, Timely, Efficient, Equitable, Effective, and Patient-
centered (STEEEP). These two historic reports were largely 
responsible for the “quality improvement” impetus that has 
advanced healthcare quality to where it is today.
However, attributing the current health care improve-
ment’s sole impetus to the IOM To Err is Human and Crossing 
the Quality Chasm would be to overlook important improve-
ment efforts that had long been in place before the IOM call 
to action. Over 100 years ago, health care improvement efforts 
were underway through the work of Boston surgeon Ernest 
Codman, MD, a strong proponent of hospital reform. His “end 
result system” is believed to have initiated outcome measure-
ment in health care and, as a consequence, the study of quality 
measures in health care began.21, 22
Around the same time on the other side of the world, 
Sakichi Toyoda was overseeing a textile company that would later 
give rise to the Toyota Motor Company. Taiichi Ohno and others 
helped take the company’s production process and codify it into 
what has come to be known as the Toyota Production System 
(TPS).23–25 TPS is a model for manufacturing centered on achiev-
ing high value through efficient production methods and simul-
taneous reduction of waste. Many of the TPS methods (better 
known as Lean management) have been adapted by the health 
care industry in efforts to reach high levels of care quality while 
truncating ever-rising costs. One of the more popular concepts of 
the TPS approach to production is Kaizan or continuous improve-
ment. Several healthcare organizations have adopted Kaizan and 
the TPS approach to pursue the IOM 6 domains of high-quality 
health care. Virginia Mason Medical Center is an example of cost 
saving in practice. Waste reduction efforts by the health system 
allowed for tremendous increases in care capacity while simulta-
neously saving millions of dollars of planned spending.26
Lean methodology is not the only quality improve-
ment framework that has evolved from decades of improve-
ment efforts in production. During the 1950s, the work of 
W. Edwards Deming, Walter Shewhart, and Joseph Juran pop-
ularized the idea of production process measurement with a
particular emphasis on reducing variation to provide greater
efficiency and effectiveness in production. Each of these men
was well respected for their individual contributions to pro-
cess improvement, however, together they produced work that
would later give rise to the modern day quality improvement
platform, the Model for Improvement.23 This model has proven
to be extremely successful with a roster of achievements involv-
ing hundreds of health care organizations around the world.27
In the late 1980s, Donald Berwick, a Boston pediatri-
cian, (later the head of the Centers for Medicare and Medicaid 
Services (CMS) appointed by President Barack Obama) together 
with leaders from the Juran Institute created the National 
Demonstration Project on Quality Improvement in Health Care. 
The goal of this effort was to examine whether current quality 
improvement methods, successful in other business domains, 
could achieve similar success in the health care setting. In 1991, as 
a result of these efforts, the Institute for Healthcare Improvement 
(IHI) was created. Today, the IHI continues its mission of health-
care improvement with the Triple Aim, improving the experi-
ence of care, improving health of populations, and reducing per 
capita costs of health care.28 These aims have been expanded to 
include a focus for the well-being of care providers in response 
to the escalating rate of physician burnout.29, 30 The evolution of 
healthcare improvement began over a century ago, and whereas 
the IOM papers reinvigorated efforts to provide higher quality 
healthcare in early 2000, disparities in care persist.
THE ONGOING GAP IN HEALTH CARE QUALITY
Despite the productive landscape in healthcare improve-
ment over the past 2 decades, a gap persists between the goal of 
high-quality, reliable care and the everyday practice of today. 
Several studies immediately following the IOM’s reports solidi-
fied the presence of these disparities that have continued to the 
current day.
In 2003, McGlynn and colleagues demonstrated that just 
over half  of adult patients in general medicine receive the rec-
ommended preventative care by their providers during health 
visits. A  similar percentage was seen in the provision of rec-
ommended care for patients with chronic conditions including 
diabetes, asthma, and congestive heart failure among others.31 
Subsequent evaluation of contributing factors failed to find 
meaningful contributions from race or socioeconomic status in 
explaining these deficiencies in the provision of recommended 
care.32 A study published 4 years later by Mangione-Smith and 
colleagues, randomly sampled pediatric patients from 12 met-
ropolitan areas and demonstrated that children receive roughly 
47% of the recommended care by their providers.33 Variation in 
practice spans both outpatient and inpatient settings as demon-
strated by Jha etal who showed significant deviation from rec-
ommended care delivered to hospitalized adult patients with 
acute myocardial infarction, congestive heart failure, or pneu-
monia using 10 widely accepted quality metrics.34
Although the study of quality deficits in healthcare has 
been rigorous and efforts to close the gap persistent, recent 
studies continue to show a deficit in the provision of up-to-date 
care consistent with current professional knowledge. Recent 
examples of quality gaps in the care of IBD include a survey 
demonstrating that nearly 30% of gastroenterologists were una-
ware of guidelines recommending the use of thromboembolic 
prophylaxis in hospitalized IBD patients35 ,and a survey of 
dermatologists and gastroenterologists demonstrated that only 
46% of providers were aware of the association between non-
melanoma skin cancer and immunosuppressive agents 6-mer-
captopurine and azathioprine.36
Knowledge gaps are not the only deficits to persist in 
healthcare. Among the IOM 6 dimensions of care quality, time-
liness of IBD care also demonstrates room for improvement. 
Dykes et al identified pediatric IBD patients who lacked timely 
follow-up after disease flare or medication change potentially 
exposing them to therapy complications and/or persistence of 
uncontrolled disease.37 An inability to provide consistent and 
timely follow-up for patients with chronic illness serves as a dir-
ect threat to quality and optimal patient outcomes.
These studies demonstrate the present need for focused 
improvement initiatives targeted at the direct contributors to 
the suboptimal  quality of health care. Persistence of prac-
tice variation, perpetuation of knowledge gaps, rising health 
care costs, provision of unnecessary care, underutilization of 
important preventative services, and preventable complications 
remain at the forefront of targets to improve the value of health 
care. A  considerable amount of work lies ahead if  we are to 
improve patient care when simultaneously constraining cost 
and improving value.23
CHALLENGES FOR IMPROVING QUALITY IN IBD
Care Complexity
The provision of care for patients with chronic illnesses such 
as IBD is complex. Achieving excellence in this dynamic care sce-
nario requires a strategic approach incorporating both patient and 
care team. The Chronic Care Model38 is an approach to chronic dis-
ease management emphasizing collaboration between an engaged, 
knowledgeable patient and a prepared, proactive provider. The 
coordinated, multidisciplinary Chronic Care Model has proven 
successful in the approach to chronic disease management in both 
pediatric and adult populations39, 40; however, this model has yet 
to be universally practiced by providers in all specialties at scale.41
Conflation of Quality Assurance with Quality 
Improvement
Quality assurance programs (QA) have steadily become 
a top priority in health care in recent years and play an instru-
mental role in the provision of high-quality and reliable care. QA 
programs pursue measurement and reporting of quality met-
rics often used by payers to incentivize the reporting of quality 
metrics, presumably as a way to demonstrate the quality of care 
provided.42 Although vital to ensuring the provision of high-qual-
ity care, QA differs from quality improvement (QI). In contrast 
to QA, QI initiatives are rooted in hypothesis-driven testing of 
novel ideas believed to advance the quality of a specific aspect of 
care. The improvement process involves generating a target aim, 
development and implementation of testing cycles with a defined 
sequence of steps, measurement protocols, and analysis of results.
Manifestation of this hypothesis-driven approach is the 
previously mentioned Model for Improvement. Refined through 
the work of Associates in Process Improvement, the Model for 
Improvement is comprised of several components beginning 
with 3 important questions to frame the improvement project: 
(1) What are we trying to accomplish?, (2) How will we know that
a change is an improvement? ,and (3) What change can we make
that will result in improvement? These questions are followed by
the Plan-Do-Study-Act (PDSA) cycle(s), an iterative sequence
of testing of process changes (“small tests of change”). The
iterative PDSA cycles are designed to organize repeated efforts
directed towards achievement of a well-defined improvement
aim. Strategies that prove beneficial move on to subsequent
steps of larger scale implementation, whereas changes not pro-
viding benefit are discarded.
Care providers and healthcare systems invest a great deal 
of time and energy into QA, however, doing so does not guar-
antee quality improvement. The pursuit of advancing quality in 
IBD should involve efforts in both QA and QI.
Variation
Variation in health care practice is a major driver for 
substandard IBD care and is often used as a surrogate marker 
to represent deficiencies in care delivery. Variation can signal 
underuse, overuse, or misuse of medical and/or surgical care.43, 44 
Drivers for variation in IBD care may include the heterogeneity 
of IBD phenotypes, breadth of therapeutic strategies available, 
and/or the lack of practice guidelines that have been studied for 
their impact on patient outcomes. Practice variation has long 
persisted in the field of IBD medical care with little to no evi-
dence to show an improving trend. In a 2007 study of treatment 
strategies in adult CD, health care providers from both commu-
nity centers and specialty centers demonstrated high rates of 
variation in treatment strategies using 5-ASA, immunomodu-
lators, and biologic therapies. Not only was this variation seen 
between provider groups but also within provider groups.45 
A similar study was conducted in the pediatric CD population 
that demonstrated high rates of variation in treatment strate-
gies.46 Variation in approaches to IBD management contributes 
to the heterogeneity in patient outcomes.
Overuse
Health care expenditures remain disproportionately high 
in the US compared to other Western countries, yet health 
outcomes are no better.47 This imbalance has been attributed, 
in part, to health care service overuse.48, 49 Overuse represents 
excessive and unnecessary care that drives up health care cost 
without advancing levels of health.49 In addition to the inef-
ficiency overuse creates, it also places patients at higher risk 
for complications. This is particularly important in the care of 
patients with IBD. An area of overuse that has drawn recent 
attention is emergency department (ED) utilization. The ED 
is a high cost setting that is not designed for improving long-
term outcomes. Between 1994 and 2005, the annual number of 
ED visits for IBD-related concerns rose from 28,000 to 76,000 
visits.50 In a multicenter pediatric study, close to 20% of ED 
visits by IBD patients were deemed unnecessary. In that study, 
drivers for ED visits included disease severity, time of day, and 
physician instruction.51 Although ED visits frequently involve 
important acute care needs, high utilization of the ED in non-
acute scenarios of IBD signals an important area for improve-
ment that has not yet been fully addressed.
Underuse
Although overuse is the predominant trend in health 
care, service underuse is equally detrimental to the provision 
of quality care. Health care underuse fails to provide services 
that keep patients healthy and subsequently eliminate the need 
for acute care or progression of disease activity often requiring 
escalation of therapy. IBD medication adherence and appro-
priate prescribing have long been a target for improving patient 
remission rates and reducing disease progression and compli-
cation. Underuse of prescribed therapy by patients continues 
to plague the field of IBD therapy. In a study conducted by 
Trindade et  al, medication adherence by patients was overes-
timated by 67% of treating physicians potentially motivating 
unwarranted escalation of therapy and associated risks.52 In a 
recent study of elderly IBD patients, close to 97% of applic-
able patients eligible for steroid-sparing biologic therapy were 
not on anti-TNF alpha agents resulting in prolonged exposure 
to steroid-based immunosuppression.53 Underuse of appropri-
ate therapeutic agents contributes significantly to morbidity 
through disease progression and increase in potentially prevent-
able disease complications.
Misuse
Within the spectrum of healthcare utilization, misuse is 
often considered a surrogate for medical errors, provision of 
the wrong care, or unwarranted exposure to risk (diagnostic 
or therapeutic). Management of patients with IBD requires 
interval assessments by objective measures. Endoscopy and col-
onoscopy have been the cornerstone of diagnostic evaluation 
in IBD. A study of lower endoscopy procedures in pediatrics 
found roughly 40% of procedures, driven by concerns for IBD, 
showed no pathologic abnormality. Among the results, authors 
concluded that a subset of normal colonoscopies could have 
been avoided.54 It is important to note that normal studies often 
provide clinically relevant information and should not be dis-
counted.55 Endoscopic study of the intestinal track through its 
documentation of mucosal healing, or lack thereof, is an impor-
tant source of information guiding therapeutic decision-mak-
ing in IBD. However, invasive testing also represents significant 
risk exposure via sedation and procedural risk. Judicious use of 
such testing is important, because misuse of invasive interven-
tions is a modifiable source of poor quality of care.
CURRENT INITIATIVES FOR IBD
Given the chronic nature of IBD and the high frequency 
of interactions with the health care system, patients with IBD 
stand to gain significant benefit from improved care quality. 
Several U.S. advocacy and provider groups have taken it upon 
themselves to advance IBD’s improvement efforts in hopes of 
making potential patient benefit a reality. These advocacy and 
provider groups include the ImproveCareNow collaborative net-
work (ICN), the Crohn’s & Colitis Foundation, the American 
Gastroenterological Association (AGA), and the American 
College of Gastroenterology (ACG). These groups have made 
meaningful advances over the past several years with respect to 
defining, measuring, and enhancing the quality of care in IBD.
ICN 
The (ICN) was established in 2007 as a consortium of 
8 core centers, with the global objective of improving the care 
and health of all children and adolescents with CD and UC. 
The initial work of the collaborative focused on developing 
consensus guidelines for pediatric IBD diagnosis and man-
agement, creating an infrastructure for standardized data col-
lection ,and tracking well-defined outcomes across centers. 
Over the past decade, ICN has grown into an international QI 
consortium comprised of 107 pediatric gastrointestinal (GI) 
centers, including 95 in United States, 2 in England, 1 in Qatar, 
and 9 in Belgium. Currently, 32,000 patients are registered in 
the network, and data from 215,000 visits have been collected 
and analyzed. As such, ICN is the largest and fastest growing 
pediatric IBD registry in the world.
Figure 1 shows the key driver diagram for ICN. As indi-
cated, the primary measurable outcome is remission rate, which 
is defined by a physician global assessment of disease activity. 
The 7 key drivers for improving remission rates that have been 
identified by the consortium are: (1) optimal access to care; (2) 
a prepared and proactive practice team; (3) accurate diagno-
sis and disease classification; (4) appropriate drug selection and 
dosage; (5) optimal nutritional intake; (6) optimal psychosocial 
health; and (7) informed patients and families who can engage 
in self  management.
Over the past decade, demonstrable improvements have 
been made for pediatric IBD patients within the ICN network. 
Remission rates have increased from 52% to 81%. Importantly, 
prednisone-free remission rates also have improved from 49% to 
80%. Ninety-three percent of patients now have a satisfactory 
growth status, and 90% have a satisfactory nutritional status (up 
from 86% and 85%, respectively). Although the drivers of these 
improvements are clearly multifactorial (ie, new therapies, moni-
toring guidelines, etc.), the improvement model practiced by ICN 
is clearly enhancing the care of pediatric IBD patients within the 
network.
Crohn’s and Colitis Foundation
The Crohn’s & Colitis Foundation has developed a 
multicenter learning health system called “IBD Qorus”, 
which is comprised of  30 community-based and academic 
FIGURE 1. Key driver diagram for ICN.
gastroenterology practices focused on IBD. This program 
is designed to facilitate interactions between patient/pro-
vider and providers with one another, to improve care. The 
specific aims of  the project include defining the standards 
of  care in IBD, developing an implementation program to 
deliver and measure the standards of  care, conducting con-
tinuous evaluation and refinement of  the process and meas-
ure, and improving the impact of  standards of  care on IBD 
patient outcomes.56 IBD Qorus has developed initiatives that 
have focused on the standardization of  care processes and a 
focus on patient outcomes. For example, a Qorus initiative 
to improve access to urgent care services has yielded several 
potential strategies shared by practices within the program 
to help identify and treat patients in need of  urgent access to 
care. Qorus has also developed standardized Care Pathways 
for the identification, assessment, and management of  anemia 
and malnutrition in IBD. The shared interests and team-
based approaches of  each individual site within the program 
facilitates rapid uptake, testing, and learning of  each aspect 
of  care improvement that has led to iterative changes in the 
pathways over time.
AGA 
In 2011, the AGA released the adult IBD Physician 
Performance Measure Set that was the product of  a multi-
stakeholder work group with representation from the AGA, 
the American Society of  Colon and Rectal Surgeons (ASCR), 
Crohn’s & Colitis Foundation, Physician Consortium for 
Performance Improvement (PCPI), and representatives from 
the family practice, research, patient, and payor communi-
ties.57 The goal of  this workgroup was to create a set of  meas-
ures for accountability and performance measurement. This 
final AGA performance set included the measures listed in 
Table 1.
The AGA IBD measure set also included a measure for 
tobacco use screening and cessation, and 2 inpatient measures 
(Clostridium difficile infection and VTE prophylaxis) that were 
not included in the CMS IBD Measure group. This measure 
group was also used in a variety of accountability programs 
including Bridges to Excellence (BTE),58 which is a program of 
the Health Care Incentives Improvement Institute that aimed 
to link demonstration of high-quality IBD care with incentives 
from health insurers.59 Uptake of this program was minimal 
and was discontinued in 2015.
With the exception of  removing the measure refer-
encing documentation of  IBD type and transitioning the 
influenza and pneumococcal measures from IBD-specific 
to broad based cross-cutting measures, the IBD measure 
group remained largely unchanged until the passage of  the 
Medicare Access to Radiology Care Act legislation creating 
the Quality Payment Program (QPP). Only 2 of  the original 
IBD measures are currently included for reporting in the 
QPP60:
- Preventive Care: Corticosteroid- Related Iatrogenic Injury –
Bone Loss Assessment
- Assessment of Hepatitis B Virus Status before Initiating
Anti-TNF Therapy
Although CMS did not provide a rational for its rule-
making, the decision to limit these measures in the QPP was 
likely influenced by relatively high performance on all measures. 
These high levels of performance suggested that the measures 
may have been “topped out” and that opportunities for fur-
ther improvement were limited. Additionally, the Core Quality 
Measures Collaborative that included private payers and CMS 
chose to include only these 2 IBD measures in its core gastroen-
terology set that preceded the finalization of the QPP.61
The challenge of relying on quality assurance measures, 
such as the original IBD measure set to improve quality, is that 
it narrowly focuses QI efforts around the specifications of these 
measures. This impact will be even more pronounced with the 
further narrowing of measures in the QPP. Furthermore, there 
is evidence to suggest that quality assurance measures do not 
improve quality, and in some cases, cause harm.62, 63 Similarly, 
the literature suggests that incentive programs such as pay 
for performance have limited to no impact on the quality of 
care.64, 65 These limitations offer an opportunity for the field to 
further embrace collaborative quality improvement initiatives 
such as those organized by the ICN and the Crohn’s & Colitis 
Foundation.
A second major effort of the AGA in advancing the qual-
ity of care in IBD has been the creation of several Clinical Care 
Pathways and Treatment Algorithms. Developed through a 
multistakeholder process, the Clinical Care Pathways incorpo-
rate expert consensus and meta-analytic methodology to pro-
duce current state-of-the-art algorithms rooted in the principles 
of evidence-based medicine. The pathways are further rein-
forced through the addition of clinical support tools and other 
quality products aimed at implementation of expert-derived 
Table 1: AGA IBD Clinical Performance Measures
Clinical Performance Measures
IBD: Type, anatomical location, and activity all assessed
IBD preventive care: Corticosteroid sparing therapy
IBD preventive care: Corticosteroid- related iatrogenic injury – 
bone loss assessment
IBD preventive care: Influenza immunization
IBD preventive care: Pneumococcal immunization
Testing for latent TB before initiating anti-TNF therapy
Assessment of hepatitis B virus before initiating anti-TNF 
therapy
Testing for Clostridium difficile – inpatient measure
Prophylaxis for venous thromboembolism – inpatient measure
IBD preventive care: Tobacco user – screening and cessation 
intervention
care strategies for the practicing GI clinician. Current IBD 
topics include the Identification, Assessment, and Initial 
Medical Treatment in CD ,66 the Identification, Assessment, 
and Initial Medical Treatment of UC,67 Drug Therapy for 
CD,68 Management of CD D after Surgical Resection,69 and 
Therapeutic Drug Monitoring.70 Clinical Care Pathways will be 
reviewed annually and assessed for ongoing relevance, specific 
major or minor revisions, and the overall need for update as 
other professional societies may have produced similar, more 
current guidelines negating the need for AGA updates.71 The 
prospective evaluation and validation of these pathways and 
clinical tools will play a critical role in ensuring relevance and 
ongoing impact on patient care.
ACG
A recent effort by the ACG to advance the quality of care 
delivered to patients with GI disease, and by extension IBD, is 
the Gastrointestinal Quality Improvement Consortium, LTD. 
(GIQuIC). This initiative is a collaborative effort along with 
the American Society for Gastrointestinal Endoscopy (ASGE) 
to develop a quality benchmarking registry aimed at provid-
ing “reliable and relevant” measures of endoscopic quality to 
empower physicians to improve patient care based on these 
metrics.72 The data collected for this registry is guided by a pre-
vious joint effort by the ACG and ASGE that identified pro-
cedural quality indicators focused on high-quality endoscopy 
ensuring that each patient receives the indicated procedure, 
yielding the correct diagnosis, and minimizing exposure to 
risk.73 Implementation of this collaborative project integrates 
experience and know-how to improve procedural outcomes in 
GI disease workup and management, including IBD.
The ACG also has made contributions to clinical care 
pathways in IBD . Aimed at empowering collaboration between 
the gastroenterologist and primary care team, the ACG recently 
published guidelines regarding preventative care in IBD updat-
ing current management strategies for risks associated with the 
chronic diseases.74
DRIVING IMPROVEMENT FORWARD: TARGETS 
FOR CONTINUING IMPROVEMENT
The work of groups like the ICN network, the Crohn’s 
& Colitis Foundation, the AGA, and the ACG advance the 
mission of improving care quality in IBD here in the USand 
abroad. Internationally, the United Kingdom (UK) has made 
significant advances in IBD care quality through the work of an 
IBD Standards group whose most recent 2013 update sought 
to “ensure that patients with IBD receive consistent, high qual-
ity care and that IBD services throughout the UK are knowl-
edge-based, engaged in local and national networking, based 
on modern IT and meet specific minimum standards”.75 The 
UK’s retooling of IBD clinical practice came in response to 
the variation in IBD care observed throughout the region and 
has brought success. Organizing bodies in the UK continue to 
review provider practice to ensure ongoing quality standards 
and performance measures are achieved.76
Advancing IBD quality further will require sustaining 
current improvement efforts when focusing on the problems 
and challenges posed by an evolving disease process, evolving 
patient population, and evolving health care system.
Variation
Variation has proven to be a major driver of substand-
ard care.77–79 The ICN network in pediatric IBD has advanced 
the understanding of care standardization and the impact 
international collaboration can have on important pediatric 
health outcomes.80 These outcomes are not limited to the field 
of pediatric IBD, as the increasing rates of disease remission 
in the face of reduced steroid exposure also can be transposed 
to adult IBD populations. Continued practice standardization 
can be achieved through high- quality comparative effective-
ness research focused on high impact treatment decisions, dis-
semination of new evidence through rigorous development of 
practice guidelines, and careful measurement and analysis of 
resulting patient outcomes. Practice guidelines that have proven 
effective can then be shared among a network of providers 
and institutions, as demonstrated in the work of the ICN net-
work. This approach to reducing practice variation through 
the spread of knowledge from learning networks will play an 
important role in IBD care moving forward.
Health Technology Platforms
Collaboration has been shown to influence and benefit 
the care of patients with IBD80 and may be facilitated by health 
information technology and platforms that foster the shar-
ing and spreading of relevant information. For example, the 
Crohn’s & Colitis QORUS project provides a platform to facili-
tate data gathering, display, and analysis in the care of IBD. 
The ICN network also has harnessed innovative information 
technology to measure and improve care in pediatric IBD. At 
participating practices, data collection is embedded in the pro-
cess of clinical care delivery, and the transfer of clinical data 
to the registry is partially automated through electronic data 
transfer. Registry data are available in near real time to sup-
port performance measurement, population measurement, and 
previsit planning, allowing real-world comparative effective-
ness research. Within ICN, an electronic “Exchange” and other 
technology and communication platforms have been developed 
to facilitate the sharing, scaling, and spreading of effective care 
practices.
System and Provider Alignment
Misalignment of care team and healthcare system often 
leads to a system of “work-arounds”.81 Work-arounds fuel 
practice variation that perpetuates suboptimal patient care.81–83 
Aligning care team and institutional visions for improvement 
will result in a care environment primed for innovation and 
collaboration. At the microsystems level, physicians, nurses, 
social workers, and other care team members work in concert 
using lessons from learning consortiums. These microsystems 
cannot scale to the macrosystem level without commitment and 
buy in from senior leadership. Together, a top-down and bot-
tom-up approach efficiently drives improvement throughout 
the culture of a healthcare system producing supportive and 
motivating work environments. Such environments eliminate 
the need for provider work-arounds and play a role in reducing 
the escalating rate of provider burnout, another threat to the 
quality of care.84, 85
Quality Metrics
In recent years, dozens of iterations on quality metrics 
have been produced.86 Consensus regarding parsimonious yet 
thorough measurement sets remains difficult and may be the 
primary challenge for the implementation of quality metrics in 
IBD. Avendis Donabedian published an articulate and concise 
model for organizing quality measurement and improvement 
initiatives.87 The model is comprised of 3 domains (Table  2): 
structural measures, process measures, and outcome measures. 
Studies have evaluated the strengths and weaknesses of each 
domain in developing innovative strategies to quality improve-
ment in IBD.88–90 Many of these studies highlight the difficulty 
in using outcome measures for IBD improvement initiatives cit-
ing challenges of time horizon, confounding, and limitations in 
the understanding of causal relationships between healthcare 
efforts and IBD outcomes.88 These challenges have deterred 
improvement initiatives from including outcome measures, 
and as a result, there has been a failure to set meaningful care 
benchmarks in IBD.
Most quality initiatives to date have focused primarily 
on process measures because they provide a feasible method 
for service accounting in the current pay-for-performance 
healthcare design.91 Process measures such as documentation 
of serologic titers, health maintenance efforts, and cancer sur-
veillance all serve important roles within IBD care74, 92; how-
ever, they do not advance the leading edge of patient outcomes 
further than where they are currently. Additional outcomes to 
strive for include metrics that capture expeditious return of 
quality of life, efficient induction and maintenance of disease 
remission, and/or longitudinal measures of mucosal healing.
As IBD care moves further into the 21st century, patients 
and providers alike must be ambitious and nimble in defining 
meaningful outcomes for the changing future healthcare envir-
onment. To do so, we must begin by acknowledging several 
aspects of measurement sets. First, metrics encompass multiple 
aspects of care. No single metric can capture the breadth of IBD 
care nor can a single metric summarize each patient’s unique 
experience of reliable care and the impact such care has on the 
multiple facets of that patient’s life. Second, measurement sets 
need to be aligned to support one another across structure, pro-
cess, and outcome without being too burdensome. Therefore, 
measurement sets should be parsimonious and scenario spe-
cific (new diagnosis vs established, inpatient vs outpatient, ED 
visit, etc.). Creating metrics that span the spectrum of care will 
identify gaps in systems-level provision of care and help unify a 
healthcare system that has become highly fragmented.
Lastly, outcome metrics should center on data-driven 
planning aimed at keeping healthy patients healthy, speeding 
recovery of patients amidst a disease flare, reducing ED vis-
its, reduction of unwarranted invasive testing and/or radiation 
exposure, and emphasizing the unique aspects of health most 
important to individual patients. These are ambitious goals. 
However, small directed tests of change carried out on a con-
sistent basis, in supportive healthcare settings, and shared over 
collaborative networks can lead to attainment of seemingly 
impossible goals.
Table 2: Donabedian Model with Domain Descriptions from AHRQ93, 94 and Examples for the IBD Population
Domain Description IBD Examples
Structural Structural measures are characteristics of the larger care setting including measures 
of the human and material resources available to the health care system and organ-
izational factors
Electronic medical records, accreditation 
status, and nurse or medical assistant 
availability.
Examination room number and turnover.
Hospital volume, teaching status, staff  de-
ployment, and qualifications
Process Process measures describe activities performed for, on behalf of, or by a patient. 
Process measures are often the first to benefit from evidence- based guidelines, 
however, are also often the first to suffer from provider practice variation. Process 
measures provide a better estimate and are more sensitive and responsive to 
change. These measures are easier to quantify and associate with outcomes.
Scheduling of surveillance colonoscopies, 
yearly influenza vaccination rates, and 
additional health maintenance items
Controller medication (such as 
immune-modulators) refill rates.
Outcomes Outcome measures describe what happens to patients as a result of the care received. 
Outcome measures are the best reflection of the impact care has on the patient; 
therefore, patients have a particularly vested interest in outcome measures as they 
closely reflect the individual’s health status.
Disease activity/remission, surgical interven-
tions, steroid exposure rates, hospitaliza-
tion rates, or admission lengths of stay.
Patient Reported Outcomes (PROMs)
CONCLUSION
The US healthcare quality improvement efforts had been 
in place long before the IOM papers, To Err is Human and 
Crossing the Quality Chasm. Although efforts were already well 
established, these landmark reports highlighted the persistent 
failing performance of the healthcare industry to provide safe, 
high-quality, and reliable care.
Despite the reinvigorated QI efforts seen at the turn of 
the 21st century, healthcare quality continues to be lacking due 
in part to high care complexity; persistence of practice varia-
tion; and the overuse, underuse, and misuse of care.
IBD, like many chronic diseases, stands to benefit greatly 
from higher quality care due to the persistent need for disease 
maintenance, high frequency of interaction with the healthcare 
system, and the significant financial and patient cost when the 
therapeutic relationship between patient and healthcare sys-
tem breaks down. Efforts such as those of the ICN network, 
Crohn’s & Colitis, AGA, and ACG will drive IBD care quality 
forward in the coming years. These efforts can be augmented 
exponentially through additional work in implementation of 
data-driven outcome measures tailored to patient and care 
scenario, reduction of practice variation, and facilitation and 
scale via health technology platforms. Microsystem functioning 
within the care team can only be scaled with buy in from sen-
ior leadership. Healthcare systems committed to production of 
high- quality and reliable care both from a bottom-up and top-
down approach will prove to be most successful as the emphasis 
on quality of care continues to permeate throughout health-
care. Although these are difficult aims to achieve, improving 
outcomes will not only enhance the health of patients, but also 
the health of the US.healthcare system as well.
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